TAS-119

Catalog No. :
ACMQBT481
CAS No. :
1453099-83-6
Molecular Formula :
C23H22Cl2FN5O3
Molecular Weight :
506.36

IUPAC Name:1-(2,3-dichlorobenzoyl)-4-((5-fluoro-6-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-2-yl)methyl)piperidine-4-carboxylic acid

TAS-119 structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
10mg98%$92.00Login to see priceIn stockInquiry
25mg98%$176.00Login to see priceIn stockInquiry
50mg98%$299.00Login to see priceInquiryInquiry
100mg98%$509.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameTAS-119
IUPAC Name1-(2,3-dichlorobenzoyl)-4-((5-fluoro-6-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-2-yl)methyl)piperidine-4-carboxylic acid
Molecular FormulaC23H22Cl2FN5O3
Molecular Weight506.36
SMILESO=C(C1(CC2=NC(NC3=NNC(C)=C3)=C(F)C=C2)CCN(C(C4=CC=CC(Cl)=C4Cl)=O)CC1)O
InChI KeyPLAVWQHGBMTMFR-UHFFFAOYSA-N
SynonymUNII-6A57J83J27 | 1453099-83-6 | CS-0138153 | TAS119 | TAS-119 | 1-(2,3-Dichlorobenzoyl)-4-((5-fluoro-6-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-2-yl)methyl)piperidine-4-carboxylic acid | VIC1911 | AKOS040754143 | VIC 1911 | 4-Piperidinecarboxylic acid, 1
CAS No.1453099-83-6

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319
Precautionary Statement(s)
P264-P270-P280-P301+P312+P330-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364-P501

Synthetic Route by SureRoute

1. ACMQBT481 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACMQBT481 route product structure diagram
    ACMQBT4811453099-83-6 In Stock
Inquiry

2. ACMQBT481 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACMQBT481 route product structure diagram
    ACMQBT4811453099-83-6 In Stock
Inquiry

Comments (0)